MediWound Ltd. Q3 2025 Earnings Recap

MDWD Q3 2025 November 20, 2025

Get alerts when MDWD reports next quarter

MediWound delivered a robust performance in Q3 2025, advancing clinical trials for EscharEx and expanding NexoBrid manufacturing, while bolstering its financial foundation with strategic financing.

Earnings Per Share Beat

$-0.24 vs $-0.81 est.

+70.4% surprise

Revenue Beat

5429000 vs 2087250 est.

+160.1% surprise

Market Reaction

1-Day -5.6%

5-Day +1.9%

30-Day +5.1%

See MDWD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Enrollment in the VALUE Phase III trial for EscharEx is progressing well, with 40 sites activated in the U.S. and Europe, although adjustments may affect timelines.
NexoBrid's manufacturing capacity has expanded sixfold, positioning the company for future growth amidst rising global demand.
Recent equity financing of $30 million enhances MediWound's financial flexibility to pursue growth strategies.
NexoBrid achieved record quarterly revenues, with a 38% year-over-year increase reported by partner Vericel, indicating strong market penetration.
Updates from Medicare on reimbursement rates may create competitive advantages for EscharEx in the complex wound care market.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MDWD on AllInvestView.

Previous Q2 2025